Global News

Salix Pharmaceuticals, Cosmo Technologies to merge

Thursday, July 10, 2014 12:33 PM

Salix Pharmaceuticals will merge with Cosmo Technologies, a subsidiary of Italy-based Cosmo Pharmaceuticals. Salix will become a wholly owned subsidiary of Irish-domiciled Cosmo Tech, which will change its name to Salix Pharmaceuticals.

More... »

WIRB Copernicus Group

VC investment in healthcare sector soars in second quarter

Thursday, July 10, 2014 06:03 AM

More than 50% of all initial public offerings in the second quarter of 2014 were healthcare companies, as 24 venture capital-backed firms became publicly traded, compared to a more robust first quarter of 35 IPOs. 

More... »

CRF Health eCOA webinar series

Sorrento awarded up to $2.6M from NIH for bispecific antibodies

Wednesday, July 9, 2014 12:12 PM

Sorrento Therapeutics, a late-stage clinical oncology company developing new treatments for cancer and its associated pain, has received two NIH small business grants, which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. Sorrento's highly diverse, fully human G-MAB library and proprietary antibody conjugation technology platforms have broad applications beyond oncology, including other therapeutic areas such as anti-infectives and auto-immune diseases.

More... »

AbbVie outlines revised $51.3B Shire offer

Wednesday, July 9, 2014 12:08 PM

AbbVie has outlined its revised proposal for Shire of $38.38 in cash and 0.8568 ordinary shares of New AbbVie for each Shire share (the Fourth Proposal). The Fourth Proposal represents an indicative value of $87.49 as of July 7, for a total of approximately $51.3 billion.

More... »

Mariel Therapeutics to acquire Stryker's organ fibrosis assets

Wednesday, July 9, 2014 12:06 PM

Mariel Therapeutics, a clinical stage biopharmaceutical company, has entered into a definitive agreement to acquire Stryker's Bone Morphogenetic Protein-7 (BMP-7) assets for the potential treatment of osteoarthritis (OA), chronic kidney disease (CKD) and other organ fibrosis conditions including lupus and obesity.

More... »

Report: cancer immunotherapy market to hit $9B globally by 2022

Wednesday, July 9, 2014 12:05 PM

Decision Resources Group reports the immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8% annual growth) in the U.S., France, Germany, Italy, Spain, U.K. and Japan.

More... »

AstraZeneca, Max Planck Institute to create satellite chemistry unit

Wednesday, July 9, 2014 12:03 PM

The Max Planck Institute of Molecular Physiology (MPI), Germany, will establish a satellite unit in cardiovascular and metabolic disease (CVMD) with AstraZeneca's CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.

More... »

Portola, Daiichi Sankyo to collaborate on andexanet alfa study

Wednesday, July 9, 2014 12:01 PM

Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Daiichi Sankyo to study andexanet alfa, Portola's investigational Factor Xa inhibitor antidote, in phase III registration studies with Daiichi Sankyo's Factor Xa inhibitor edoxaban. Portola's original collaboration agreement with Daiichi Sankyo, announced in June 2013, covered the conduct of a phase II proof-of-concept study, for which results are anticipated later this year.

More... »

Alzheimer’s Research U.K. calls for increased investment in Alzheimer’s drug trials

Monday, July 7, 2014 10:08 AM

Alzheimer’s Research U.K. calls for increased investment in Alzheimer’s drug trials after a comprehensive study of all of the clinical trials for Alzheimer’s drugs in the U.S. highlighted a very high failure rate of the drugs being tested. The study, published in Alzheimer’s Research and Therapy, found that 99.6% of trials of potential Alzheimer’s treatments aimed at preventing, curing or improving the symptoms of the disease failed or were discontinued.

More... »

Bio-Techne to acquire Novus Biologicals

Monday, July 7, 2014 10:06 AM

Bio-Techne has acquired Novus Biologicals for $60 million in cash. Novus Biologicals is a Littleton, Colorado-based supplier of outsourced and in-house developed antibodies and other reagents for life science research. The transaction was financed with cash on hand.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs